Insulin glargine
Long-acting insulin / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Insulin glargine?
Summarize this article for a 10 year old
Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used in the management of type I and type II diabetes.[7] It is injected just under the skin.[7] Effects generally begin an hour after use.[7]
Clinical data | |
---|---|
Trade names | Lantus, Toujeo, Basaglar, others |
Biosimilars | insulin glargine-aglr, insulin glargine-yfgn, Rezvoglar, Abasaglar, Semglee |
AHFS/Drugs.com | Monograph |
MedlinePlus | a600027 |
License data | |
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Onset of action | ~1 hours[7] |
Duration of action | 24 to 36 hours[7] |
Identifiers | |
| |
CAS Number | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.241.126 |
Chemical and physical data | |
Formula | C267H404N72O78S6 |
Molar mass | 6062.96 g·mol−1 |
NY (what is this?) (verify) |
Common side effects include low blood sugar, problems at the site of injection, itchiness, and weight gain.[7] Other serious side effects include low blood potassium.[7] NPH insulin rather than insulin glargine is generally preferred in pregnancy.[8] After injection, microcrystals slowly release insulin for about 24 hours.[7] This insulin causes body tissues to absorb glucose from the blood and decreases glucose production by the liver.[7]
Insulin glargine was approved for medical use in the United States in 2000.[7] It is on the World Health Organization's List of Essential Medicines.[9] In 2021, it was the 29th most commonly prescribed medication in the United States with more than 19 million prescriptions.[10][11] In July 2021, the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product called Semglee (insulin glargine-yfgn) for the treatment of diabetes.[12]